Article Information
- Received January 20, 1998
- Revision received March 9, 1998
- Accepted March 13, 1998
- First published June 1, 1998.
- Version of record published June 1, 1998.
Author Information
- Shigeo Okabe1,
- Carlos Collin1,
- Jonathan M. Auerbach1,
- Noam Meiri2,
- Johan Bengzon1,
- Mary B. Kennedy3,
- Menahem Segal4, and
- Ronald D. G. McKay1
- 1Laboratory of Molecular Biology and
- 2Laboratory of Adaptive Systems, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892,
- 3Division of Biology, California Institute of Technology, Pasadena, California 91125, and
- 4Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
Author contributions
Disclosures
- Received January 20, 1998.
- Revision received March 9, 1998.
- Accepted March 13, 1998.
J.M.A. was supported by a Human Frontier Science Program Long-Term Fellowship. We thank Drs. M. Mayford and E. R. Kandel for the CaMK promoter, Drs. P. Seeburg and M. Hollmann for NMDA receptor cDNAs, Drs. R. J. Wenthold, B. Wolfe, M. Sheng, and A. Czernik for antibodies, and Drs. C. J. McBain and M. L. Mayer for valuable comments on this manuscript.
Correspondence should be addressed to Ronald D. G. McKay, National Institutes of Health, National Institute of Neurological Diseases and Stroke, Laboratory of Molecular Biology, Building 36, Room 5A29, 36 Convent Drive-MSC 4092, Bethesda, MD 20892-4092.
Dr. Okabe’s present address: National Institute of Bioscience and Human Technology, Tsukuba, Ibaraki 305, Japan.
Dr. Bengzon’s present address: Restorative Neurology Unit, University Hospital, Lund S-22185, Sweden.
Online Impact